Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month.

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

Theres no question that medications like semaglutide (Wegovy) and tirzepatide (Zepbound) have been making headlines lately. Theyre two of the few injectable medications approved specifically for ...

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

This data could help support Novo in its bid to claw back market share taken by Eli Lilly in the obesity space.

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

The popular weight-loss drugs Ozempic and Wegovy will soon be available at the warehouse chain Costco, as their manufacturer races to keep ahead of the competition, including many cheaper copycat ...

Eli Lilly ( LLY +2.53%) has become the leader in a market marching toward the $100 billion mark. I'm talking about the weight ...

FILE - Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia, File) Prices are falling for the popular obesity ...